Cellectis (CLLS) EBT Margin Growth (1y) (2016 - 2026)
Powered by 
Analysis
Cellectis (CLLS) EBT Margin Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -153.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -571.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 553.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4,709.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1,076.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1,911.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -392.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 29,565.00 |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -39,520.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -39,520.00 |
| Mar 31, 2026 | -17,504.00 |
| Dec 31, 2025 | 27,027.00 |
| Sep 30, 2025 | 4,568.00 |
| Jun 30, 2025 | 40,993.00 |
| Mar 31, 2025 | -23,514.00 |
| Dec 31, 2024 | 4.14 Mn |
| Sep 30, 2024 | 43,869.00 |
| Jun 30, 2024 | -297,701.00 |
| Mar 31, 2024 | 1.60 Mn |
| Dec 31, 2023 | -4.17 Mn |
| Sep 30, 2023 | 1.29 Mn |
| Jun 30, 2023 | 411,530.00 |
| Mar 31, 2023 | -1.54 Mn |
| Dec 31, 2022 | 5,106.00 |
| Sep 30, 2022 | -1.28 Mn |
| Jun 30, 2022 | -111,926.00 |
| Mar 31, 2022 | -29,831.00 |
| Dec 31, 2021 | -35,571.00 |
| Sep 30, 2021 | -3,468.00 |